UBS lowered the firm’s price target on Acumen (ABOS) to $4 from $6 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s cash position and the market volatility for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: